Vibostolimab
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research[1].
Product Specifications
CAS Number
2231305-30-7
UNSPSC
12352203
Target
Transmembrane Glycoprotein
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vibostolimab.html
Purity
96.54
Solubility
10 mM in DMSO
Smiles
[Vibostolimab]
Molecular Weight
(144.5 kDa)
References & Citations
[1]Niu J, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. Ann Oncol. 2022 Feb;33 (2) :169-180.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
DFA71990-01 1 mg
7- (3- (3-Hydroxy-4- (4'-iodophenoxy) -1-butenyl) -7-oxabicyclo (2.2.1) heptan-2-yl) -5'-heptenoic acid
Sign In for Pricing
View Details DFA71990-02 5 mg
7- (3- (3-Hydroxy-4- (4'-iodophenoxy) -1-butenyl) -7-oxabicyclo (2.2.1) heptan-2-yl) -5'-heptenoic acid
Sign In for Pricing
View Details DFA71990-03 10 mg
7- (3- (3-Hydroxy-4- (4'-iodophenoxy) -1-butenyl) -7-oxabicyclo (2.2.1) heptan-2-yl) -5'-heptenoic acid
Sign In for Pricing
View Details DFA71990-04 25 mg
7- (3- (3-Hydroxy-4- (4'-iodophenoxy) -1-butenyl) -7-oxabicyclo (2.2.1) heptan-2-yl) -5'-heptenoic acid
Sign In for Pricing
View Details